Clearmind Files Hong Kong Patent for MEAI-PEA Depression Therapy
Clearmind Medicine filed a Hong Kong patent application for a novel depression therapy combining its proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA). The non-hallucinogenic treatment targets major depressive disorder in a market projected to exceed $25 billion by 2030.
1. Patent Filing in Hong Kong
Clearmind Medicine submitted a patent application to the Hong Kong Intellectual Property Department for its MEAI-PEA combination therapy aimed at treating major depressive disorder. This filing covers the synergy of 5-methoxy-2-aminoindane and Palmitoylethanolamide under a non-hallucinogenic neuroplastogen approach.
2. Innovative Non-Hallucinogenic Therapy
The therapy blends Clearmind’s proprietary MEAI with Palmitoylethanolamide sourced via the company’s partnership with NeuroThera Labs, intending to provide an accessible alternative to SSRIs. The non-hallucinogenic profile could address safety and affordability concerns tied to existing antidepressants.
3. Market Opportunity for MDD
Major depressive disorder affects over 332 million people globally, and the antidepressant market is expected to surpass $25 billion by 2030. If approved, this MEAI-PEA therapy could capture unmet demand in a large and growing treatment market.